Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salmefamol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 18/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoterol SCHEMBL3700946 | 0.92 | ADRB2 (0.65) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Salmefamol SCHEMBL30361710 | 0.89 | ADRB2 (0.67) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Salmefamol SCHEMBL20285629 | 0.89 | ADRB2 (0.67) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Salmefamol SCHEMBL18458 | 0.89 | ADRB2 (0.67) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Arformoterol SCHEMBL6426856 | 0.87 | ADRB2 (0.77) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Arformoterol SCHEMBL750656 | 0.87 | ADRB2 (0.77) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Arformoterol SCHEMBL328968 | 0.84 | ADRB2 (0.80) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Arformoterol SCHEMBL14890289 | 0.84 | ADRB2 (0.61) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Albuterol SCHEMBL9238360 | 0.83 | ADRB2 (0.75) | ADRB2ADRB1CYP2D6TSHRCYP1A2 | |
| Levosalbutamol SCHEMBL18527021 | 0.83 | ADRB2 (0.75) | ADRB2ADRB1CYP2D6TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020393-B1 | FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY | 3M INNOVATIVE PROPERTIES CO (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2512438-B1 | FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY | 3M INNOVATIVE PROPERTIES CO (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-3020393-A1 | FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY | 3M Innovative Properties Company of 3M Center (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20120272951-A1 | FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY | 3M INNOVATIVE PROPERTIES COMPANY | 2012-11-01 | — | — | US | disclosed |
| EP-2512438-A2 | FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY | 3M Innovative Properties Company (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011084316-A2 | FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20090123391-A1 | Novel Formulations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | US | disclosed |
| EP-2012797-A2 | NOVEL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-1996158-A2 | NOVEL FORMULATIONS | 3M Innovative Properties Company (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007117911-A2 | NOVEL FORMULATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007109698-A2 | NOVEL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123391-A1 | Novel Formulations | PFN1, CCL11, MFAP1 | ADRB2 61/4885ADRB1 79/4885CYP2D6 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.